Join to view full profile
10 E 102nd StNew York, NY 10029
Phone+1 212-241-6756
Fax+1 212-731-5210
Dr. Kremyanskaya is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2009 - 2012- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2006 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2006
Certifications & Licensure
NY State Medical License 2008 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.Charles Hertz, Nikolaos Spyrou, Ronald Hoffman, Cansu Cimen Bozkus, Nina Bhardwaj
Leukemia. 2026-08-18 - Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis.Marina Kremyanskaya, Yelena Z Ginzburg, Ronald Hoffman
Blood. 2026-03-19 - A novel 3-way translocation involving::drives AML with eosinophilia.Ariel Siegel, Joseph Tripodi, Dianna Hardatt, Brianna Kelly, Sebastian El Ghaity-Beckley
Blood Neoplasia. 2025-05-01
Press Mentions
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021May 12th, 2021- Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia VeraDecember 18th, 2020
- Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual MeetingNovember 4th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
